Grand River Aseptic Manufacturing (GRAM), a parenteral drug contract development and manufacturing organization (CDMO), held a sustainability celebration and a local park cleanup on April 21.
Grand River Aseptic Manufacturing (GRAM), a sterile injectable pharmaceutical contract manufacturer of biologics, small molecules, and vaccines, announced the approval of Bavarian Nordic’s recent Biologics License Application (BLA) supplement authorizing the manufacture of JYNNEOS. In conjunction with that approval, GRAM recently hosted a regulatory inspection by the Center for Biologics Evaluation and Research (CBER) that resulted in zero observations and Federal Drug Administration (FDA) approval of the company’s expanded filling facility and new finishing center.
MEMPHIS, Tenn.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the expansion of its cell therapy contract development and manufacturing (CDMO) facility in Memphis, Tenn. The expanded space is suitable for clinical and commercial cell therapy manufacturing, with an additional nine (9) state-of-the-art processing suites, adding to an existing 16 cleanrooms.
Meanwhile, a Grand Rapids, Michigan-based CDMO landed a deal with Bavarian Nordic, to fill and finish the vaccine. Grand River Aseptic Manufacturing, a relatively new player in the CDMO world, only being around since 2010, announced it received the deal from Bavarian Nordic as well as approval from HHS and BARDA to increase the domestic supply of Jynneos.
Grand River Aseptic Manufacturing (“GRAM”), a prominent parenteral drug product contract development and manufacturing organization (CDMO), has entered into an agreement with Bavarian Nordic, a Denmark-based vaccine company, to fill and finish JYNNEOS smallpox/monkeypox vaccine. The agreement was supported by the Department of Health and Human Services (HHS) and the Biomedical Advance Research and Development Authority (BARDA) to increase domestic vaccine supply.
Grand River Aseptic Manufacturing (GRAM), a parenteral drug product contract development and manufacturing organization (CDMO), has entered into an agreement with Bavarian Nordic, a Denmark-based vaccine company, to fill and finish JYNNEOS smallpox/monkeypox vaccine. The agreement was supported by the Department of Health and Human Services (HHS) and the Biomedical Advance Research and Development Authority (BARDA) to increase domestic vaccine supply.
Grand River Aseptic Manufacturing (“GRAM”), a prominent parenteral drug product contract development and manufacturing organization (CDMO), has completed Phase II of its facility expansion which includes the installation of GRAM’s two new sterile Bausch+Ströbel filling lines. Now, with a total of three separate fill lines, GRAM’s filling capacity reaches over 50 million units per year with space to serve a greater variety of pharma and biotech customers. GRAM’s continued growth positions the company to become a leader in biotherapeutics with many new biologic capabilities and clients.
Grand River Aseptic Manufacturing (“GRAM”), a prominent parenteral drug product contract development and manufacturing organization (CDMO), has completed Phase II of its facility expansion which includes the installation of GRAM’s two new sterile Bausch+Ströbel filling lines. Now, with a total of three separate fill lines, GRAM’s filling capacity reaches over 50 million units per year with space to serve a greater variety of pharma and biotech customers. GRAM’s continued growth positions the company to become a leader in biotherapeutics with many new biologic capabilities and clients.
Over the past two years, supply chain issues have been in the spotlight as worldwide disasters like the pandemic have continually tested their strength and resilience. While the demand for some products declined exponentially, the need for pharmaceutical products skyrocketed.
Grand River Aseptic Manufacturing (“GRAM”), a leading parenteral contract development and manufacturing organization (CDMO), has signed a multi-year contract with the U.S. Department of Health and Human Services and the U.S. Department of Defense. Under the agreement, GRAM will invest $160 million and receive $120 million from the U.S. government to fund the expansions of its filling and finishing facilities.